Loading clinical trials...
Loading clinical trials...
To demonstrate the efficacy and safety of aliskiren given to patients with essential hypertension, at doses of 75 mg, 150 mg and 300 mg alone, and in combination with hydrochlorothiazide (HCTZ)
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Novartis
NCT07365332 · Pulmonary Arterial Hypertension
NCT07218029 · Pulmonary Arterial Hypertension
NCT02417740 · Cystic Fibrosis, Immunologic Deficiency Syndrome, and more
NCT06649110 · Healthy Volunteers, Pulmonary Arterial Hypertension
NCT06647511 · Gestational Hypertension
Novartis Pharmaceuticals
East Hanover, New Jersey
Investigative Centers
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions